We are live on ! Find out more
SGYP

Synergy Pharmaceuticals
SGYP

Delisted

SGYP was delisted on the 7th of March, 2019.

72 hedge funds and large institutions have $139M invested in Synergy Pharmaceuticals in 2013 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 25 increasing their positions, 24 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

260% more call options, than puts

Call options by funds: $824K | Put options by funds: $229K

4% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 24

1.68% less ownership

Funds ownership: 28.1% → 26.42% (-1.7%)

6% less funds holding

Funds holding: 77 → 72 (-5)

43% less capital inflows, than outflows

Capital inflows: $6.43M | Capital outflows: $11.3M

59% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 17

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
72
Holders Change
-5
Holders Change %
-6.49%
% of All Funds
2.08%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
7
Increased
25
Reduced
24
Closed
17
Calls
$824​K
Puts
$229​K
Net Calls
+$595​K
Net Calls Change
+$421​K

SGYP Hedge Fund Activity: Q4 2013 in Review

72 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in Synergy Pharmaceuticals (SGYP) for Q4 2013, worth a combined $139M — up 20% from $116M a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of SGYP and 7 opened new positions — a net loss of 10 holders — while 24 trimmed existing stakes and 25 added.

The largest buyer was Oxford Asset Management, opening a new position worth an estimated $2.1M. The largest seller was Fidelity Investments, cutting an estimated $3.5M.

  • 72 institutional investors held Synergy Pharmaceuticals (SGYP) as of Q4 2013, down from 77 in Q3 2013.
  • Funds reported $139M of Synergy Pharmaceuticals stock for Q4 2013, up 20% quarter-over-quarter.
  • 7 funds opened new Synergy Pharmaceuticals positions in Q4 2013 and 17 closed out, a net change of -10 holders.
  • The largest Synergy Pharmaceuticals buyer in Q4 2013 was Oxford Asset Management, an estimated $2.1M added.
  • The largest Synergy Pharmaceuticals seller in Q4 2013 was Fidelity Investments, an estimated $3.5M sold.

Based on aggregated 13F filings for Q4 2013.